

A bacterial mutation blocking P2 phage late gene expression

(*gro* mutant)

MELVIN G. SUNSHINE AND BRIAN SAUER

Department of Microbiology, University of Iowa, Iowa City, Ia. 52240; and Molecular Biology Department, University of California, Berkeley, Calif. 94720

Communicated by Allan Campbell, May 5, 1975

ABSTRACT A mutant of *Escherichia coli* strain C has been isolated, called *gro*₁₀₉, that blocks bacteriophage P2 propagation by interfering with late gene expression. DNA replication proceeds normally in P2⁺-infected *gro*₁₀₉ cells, but late phage proteins are not made. Early P2 mRNA is made in normal amounts, but very little late mRNA can be detected. P2 mutants (P2 *ogr*) able to overcome the *gro*₁₀₉ block have been isolated in which synthesis of late P2 mRNA and phage proteins is restored.

The *gro*₁₀₉ mutation is closely linked to the cluster of ribosomal genes at 64 min and is recessive to the wild-type (*gro*⁺) allele. A P2 *ogr* mutation has been mapped on the left arm of the P2 genome, between the right-most known late gene (D) and the phage attachment site. P2 *ogr* can complement P2⁺ in *gro*₁₀₉ cells, indicating that *ogr* codes for a diffusible product.

Several aspects of the host cell's role in the development of the temperate bacteriophage P2 are demonstrated by the requirements for various *Escherichia coli* genes: *rep* (1), *dnaB* (Sunshine, unpublished data), *dnaE* (*pol*_{III}), and *dnaG* (D. Bowden, personal communication). These host functions are known to affect P2 DNA replication.

The work described here was undertaken to determine whether other host functions are involved in the propagation of P2. We report the isolation and characterization of (a) a host mutation (*gro*₁₀₉) that blocks P2 late gene expression, and (b) a P2 mutant (P2 *ogr*) that can overcome the *gro*₁₀₉ block.

MATERIALS AND METHODS

Media. LB broth (LB) and LB agar (LA) are described by Bertani (2). LB agar is supplemented with 2.5 mM CaCl₂ for assaying P2. LB broth is supplemented with 80 mM MgSO₄ for preparation of Hy5 phage (3). TPG-CAA is described by Lindqvist (4). TPG complete medium contains 0.001% thymidine plus 5 μg/ml of each amino acid instead of casein amino acids. TPG low Met medium contains 19 amino acids at 5 μg/ml plus methionine at 0.25 μg/ml.

Growth and Purification of Phage. P2 phage stocks for isolating P2 DNA and mRNA were prepared and purified as described by Geisselsoder *et al.* (5). Hy5 was prepared as described by C. Bradley, P. L. Ong, and J. B. Egan (submitted for publication). Hy5 phage purification was the same as for P2.

Bacterial Strains. The bacterial strains used are described in Table 1. Strains designated C- and HF4704 were derivatives of *E. coli* strain C (6). All others are *E. coli* K derivatives.

Isolation of *E. coli gro*₁₀₉. Strain C-520 was UV-treated to 10% survival and allowed to grow through several divisions. About 10⁵ cells were plated along with about 10⁷ P2

*vir*₁. Surviving colonies were re-streaked and retested for ability to adsorb or release P2, and *rep* mutant colonies were eliminated by plating φX174 (15). One clone, number 109, did not release P2 phage, was killed by P2 *vir*₁ infection, was not *rep*, and was named C-2111.

Isolation of P2 Mutants Able to Form Plaques on Lawns of *gro*₁₀₉ Cells. P2 mutants able to form plaques on a lawn of C-2111 were isolated by plating approximately 1 to 2 × 10¹⁰ phage on LA plates heavily seeded with C-2111 and incubating at 30°. Generally, one to two plaques appeared on such plates (frequency = 10⁻¹⁰). Plaques were picked and reisolated through two passages on C-2111. Such P2 mutants are designated as P2 *ogr* for over grow on *gro*₁₀₉. The first P2 *ogr* mutants were isolated from stocks of P2 *lg*, which produces larger burst sizes than P2⁺ (16). Subsequently, *ogr* mutants have been isolated from P2⁺ stocks and shown not to differ from P2 *lg ogr* mutants other than in burst size. P2 *lg ogr*₁ will be referred to throughout this paper as P2 *ogr*₁.

Phage Strains. P2 *vir*₁ and P2 *vir*₃ are described by Bertani (17). Hy5 carries the late genes of P2 and the nonhomologous early region of phage 186 (18, 19). P2 *hy***dis* is a P2-related, heteroimmune hybrid phage (20). P2 conditional lethal mutants are described in the literature as follows: P2 *tsB*₄₀ (21); P2 *amA*₁₂₉ and P2 *amB*₁₁₆ (22); P2 *vir*₂₄ *tsB*₄₀, P2 *vir*₃ *tsD*₄, P2 *vir*₁ *amD*₆, and P2 *vir*₁ *amT*₅ (23); P2 *vir*₁ *amU*₂₅, P2 *vir*₁ *amE*₃₀, and P2 *vir*₁ *amQ*₃₄ (10). P2 *ogr* mutations were combined with P2 conditional lethal mutations as follows: P2 *vir*₃ *tsD*₄ was used to select P2 *vir*₃ *tsD*₄ *ogr*₅, and a cross with P2 *tsB*₄₀ yielded P2 *vir*₃ *ogr*₅. P2 *vir*₁ *amQ*₃₄ was used to select P2 *vir*₁ *amQ*₃₄ *ogr*₈. This strain was crossed with P2 *vir*₂₄ *tsB*₄₀ to yield P2 *vir*₁ *ogr*₈. P2 *lg ogr*₁ was crossed with P2 *hy***dis* to yield P2 *hy***dis ogr*₁, which was used to lysogenize strain C-2111. This lysogenic strain (C-2115) was infected with P2 *amB*₁₁₆ to yield a P2 *amB*₁₁₆ *ogr*₁ recombinant.

P1 Transduction Experiments. Phage P1 lysates were prepared and transduction experiments were performed as described by Sunshine and Kelly (24) with the following modification. After the bacteria in the adsorption mixture were washed with 1% saline, diluted aliquots were plated on LA plates and incubated for 4 hr at 37° before streptomycin (250 μg/ml) or spectinomycin (150 μg/ml) was added in soft agar overlays. This allowed the Str-s or Spc-s ribosomes to segregate before the antibiotic was added.

Phage Crosses. Phage crosses were performed as described by Lindahl (21) using either *E. coli* C-1a or C-520.

P2 DNA Synthesis. The extent of P2 DNA synthesis was determined by measuring incorporation of [³H]thymidine into trichloroacetic acid-insoluble material in *uvrA* cells that had been treated with mitomycin C and infected with P2 according to the method of Lindqvist and Six (25).

Detection of P2 Phage Proteins. Labeled extracts of infected cells were prepared as described by Lengyel *et al.*

Abbreviations: *gro*, a bacterial mutation that blocks phage growth at a step subsequent to adsorption; UV, ultraviolet light; Ery, erythromycin; Spc, spectinomycin; Str, streptomycin.

Table 1. Bacterial strains

Collection no.	Relevant genotype	Origin/reference
C-1a	F ⁻ , prototrophic	7
C-2	F ⁺	8
C-417	F ⁻ <i>trp arg str met pur</i>	9
C-520	F ⁺ <i>supD</i>	10
C-1055	F ⁺ , polyauxotrophic	9
C-2111	F ⁺ <i>supD gro109</i>	C-520, see text
C-2115	F ⁺ <i>supD gro109</i> (P2 <i>hy* dis ogr1</i>)	C-2111 lysogenized with P2 <i>hy* dis ogr1</i>
C-2116	F ⁺ <i>trp str gro109</i>	Recombinant: C-2111 × C-417
C-2118	F ⁻ <i>uvr thy str gro109</i>	Transductant: C-2116 donor, HF4704 recipient
C-2119	F ⁻ <i>ery</i>	From C-1a by mutation
C-2120	F ⁻ <i>spc</i>	From C-1a by mutation
C-2121	F ⁻ <i>str gro109</i>	Transductant: C-2116 donor, C-1a recipient
C-2122	F ⁻ <i>spc str gro109</i>	From C-2121 by mutation
C-2123	F ⁻ <i>ery str gro109</i>	From C-2121 by mutation
C-2128	F ⁻ <i>uvrA thy str</i>	From HF4704 by mutation
HF4704	F ⁻ <i>uvrA thy</i>	11
KLF41/JC1553	F ⁻ 141 <i>gro⁺</i>	12
1100	F ⁻ <i>end</i>	13
PM14	F ⁻ <i>end</i> (Hy5)	1100 lysogenized with Hy5

The nomenclature used follows Taylor and Trotter (14).

(26), with the following modifications: TPG low Met medium was used in place of HF medium. Cells were UV-irradiated for 4½ min, instead of 3 min, to diminish host protein synthesis background. Infected cells were diluted into TPG complete low Met medium at zero time and then labeled with [³⁵S]methionine (2.6 µCi/ml, specific activity 1.5 Ci/mmol). The time for administration of the radioactive methionine pulse was selected after determining lysis time in the UV-treated cells. Lysis of both C-2128 infected with P2 *vir3* and C-2128 infected with P2 *vir3 ogr5* occurs at 40 min after infection. Lysis of C-2118 infected with P2 *vir3 ogr5* occurs at 60 min after infection. No lysis is observed for C-2118 infected with P2 *vir3*. Labeling was from 5 to 35 min for *gro⁺* cells, and from 15 to 45 min for *gro109* cells. Labeled extracts were analyzed as described (26) on 10% polyacrylamide/dodecyl sulfate gels.

Extraction and Hybridization Analysis of Phage mRNA. Ten-milliliter cultures of cells were grown and infected as described above for labeled protein extracts, except that the infected cells were not UV-irradiated. The cultures were pulse-labeled at the indicated times for 3 min with [³H]uridine (10 µCi/ml; specific activity 28 Ci/mol). Cells were collected, lysed, and extracted with phenol as described (5). Extracts were then stored frozen at -20° for no longer than 5 days. DNA for hybridization was extracted from Hy5 and P2 *vir1* by the procedure of Thomas and Abelson (27). Hybridization conditions were as described (5) using 2-4 µg of denatured DNA per filter. Hybridization to Hy5 DNA gives a direct measure of late P2 mRNA, since the early region of this phage is not homologous with P2 (19).

RESULTS

Growth of phages in *gro109* strains

A bacterial mutant that blocks the growth of phage P2 was isolated from *E. coli* C after mutagenesis with UV. The burst size of P2 on this mutant strain (*E. coli gro109*) is less

than 0.1 phage per cell, as compared to 160 phage per cell on the parental strain. P2⁺ plates on *E. coli gro109* at an efficiency of 10⁻¹⁰. The small plaques formed at this frequency represent P2 *ogr* mutants (overcoming the *gro* block), which grow well on both *gro⁺* and *gro109 E. coli*. None of the nine independently isolated *ogr* mutants is *am* or *ts*, as shown by normal burst sizes and efficiencies of plating when grown on *E. coli sup⁻* at 30° and 42°.

The *gro109* block appears to be specific for P2 and the P2-related phages P2 *hy*dis*, 299, and Wφ. Phages P1, φX-174, R17, Qβ, λ, and T7 all plate normally on *gro109* lawns.

Mapping of *gro109* in *E. coli*

To find the chromosomal location of the *gro109* mutation, F⁺ × F⁻ crosses were performed, and linkage between *gro109* and *str* was detected. This linkage was further demonstrated by P1 transduction from a *str^r gro109* strain (C-2116) into a *str^s* strain (C-2), selecting for Str-R. Of 100 transductants tested, 58% simultaneously obtained the ability to block the growth of P2.

Nomura and Engbaek (28) have presented data indicating that the cluster of ribosomal protein genes near the *str* locus is transcribed as a single unit, a "ribosomal protein operon," and that the direction of transcription is in the order of *ery*, *spc*, *str*, and *fus*. These markers were used to more definitively map the location of *gro109*. Various *ery^r*, *spc^r*, and *str^r* derivatives of C-2116 and C-1a were constructed, and P1 lysates were prepared on them. The data in Table 2 show the results of two transduction experiments. In experiment A, Str-R was selected, and linked markers from the donor strain were efficiently transferred: 78% (71/91) of the transductants were *spc^s*, 77% (70/91) were *ery^r*, and 74% (67/91) were *gro109*. These cotransfer frequencies, along with analysis of the various classes of transductants, indicate the order *gro109*, *ery*, *spc*, *str*. The data presented in experiment B are consistent with this order. One experiment, not listed in

Table 2. Mapping of *gro*₁₀₉ by P1 transduction

Transduction	Selection	Genotypes of transductants	Frequency
A. Donor: C-2123 (<i>gro</i> ₁₀₉ <i>ery</i> ^r <i>spc</i> ^s <i>str</i> ^r) Recipient: C-2120 (<i>gro</i> ⁺ <i>ery</i> ^s <i>spc</i> ^r <i>str</i> ^s)	Str-R	<i>gro</i> ₁₀₉ <i>ery</i> ^r <i>spc</i> ^s	66/91 (73%)
		<i>gro</i> ⁺ <i>ery</i> ^s <i>spc</i> ^r	20/91 (22%)
		<i>gro</i> ⁺ <i>ery</i> ^r <i>spc</i> ^s	4/91 (4%)
		<i>gro</i> ₁₀₉ <i>ery</i> ^s <i>spc</i> ^s	1/91 (1%)
B. Donor: C-2122 (<i>gro</i> ₁₀₉ <i>ery</i> ^s <i>spc</i> ^r <i>str</i> ^r) Recipient: C-2119 (<i>gro</i> ⁺ <i>ery</i> ^r <i>spc</i> ^s <i>str</i> ^s)	Spc-R	<i>gro</i> ₁₀₉ <i>ery</i> ^s <i>str</i> ^s	37/96 (38.5%)
		<i>gro</i> ₁₀₉ <i>ery</i> ^s <i>str</i> ^r	36/96 (37.5%)
		<i>gro</i> ⁺ <i>ery</i> ^r <i>str</i> ^s	9/96 (9.4%)
		<i>gro</i> ⁺ <i>ery</i> ^s <i>str</i> ^s	8/96 (8.3%)
		<i>gro</i> ⁺ <i>ery</i> ^s <i>str</i> ^r	3/96 (3.1%)
		<i>gro</i> ₁₀₉ <i>ery</i> ^r <i>str</i> ^s	3/96 (3.1%)
Deduced order: <i>gro</i> ₁₀₉ - <i>ery</i> - <i>spc</i> - - <i>str</i>			

Transductions were performed as described in *Materials and Methods*.

Table 2, showed 90% (34/38) cotransduction of *gro*₁₀₉ with *ery*^r.

Dominance of *gro*⁺

The close linkage of *gro*₁₀₉ to *str* allowed us to determine whether *gro*₁₀₉ is dominant or recessive by construction of diploid strains. The episome, F'141, carries genetic material of *E. coli* covering *str* and adjacent genes (12). F'141-containing derivatives of C-2116 were prepared by allowing KLF41/JC1553 (F' *gro*⁺) to mate with C-2121 (F⁻ *str*^r *gro*₁₀₉) for 40 min and plating on LA for colonies. Twenty five colonies were reisolated and tested for maleness by ability to plate phage R17. Five strains were male by this test, and all five plated P2⁺ with normal efficiency. All five diploid strains were tested for ability to be cured by acridine orange (1). After acridine treatment, all five strains yielded F⁻ *gro*₁₀₉ clones at high frequency. This indicates that *gro*⁺ is dominant to *gro*₁₀₉ and that the *gro* gene produces a product that allows P2 development.

P2 DNA synthesis

P2 DNA synthesis in *gro*₁₀₉ cells was measured by the cumulative incorporation of [³H]thymidine into acid-insoluble




FIG. 1. P2 DNA synthesis in C-2118 *uvrA thy gro*₁₀₉. Cells were pretreated with 60 μ g/ml of mitomycin C for 10 min to selectively suppress host DNA synthesis, washed, resuspended in TPG-CAA plus 2 μ g/ml of unlabeled thymidine, infected, labeled with [³H]thymidine (50 μ Ci/ml, specific activity 5 Ci/mmol), and sampled at the given times. O, Untreated cells; ●, mitomycin pretreated cells; □, mitomycin pretreated cells plus P2 *ogr*⁺; ■, mitomycin pretreated cells plus P2 *ogr*₁.

material. Fig. 1 shows the incorporation of label after P2⁺ and P2 *ogr*₁ infection of *gro*₁₀₉ strain C-2118. The rate and level of incorporation were identical for both phage strains. Thus, P2⁺ DNA replicates as well as does P2 *ogr*₁ DNA in *gro*₁₀₉ *E. coli*.

Synthesis of phage proteins

Electrophoresis of ³⁵S-labeled proteins from infected and uninfected *gro*⁺ and *gro*₁₀₉ strains shows that late phage proteins are not present in P2⁺-infected *gro*₁₀₉ cells, although the early protein B can be seen (Fig. 2). The P2 *ogr*₅ mutant, on the other hand, can synthesize phage late proteins in *gro*₁₀₉ cells. Since no host protein migrates to the same position as P2 late protein H, we measured synthesis of this protein from tracings by a microdensitometer. The *gro*₁₀₉ mutation reduced H protein synthesis by P2 *ogr*⁺ at least 40-fold when compared to P2 *ogr*₅, to a level indistinguishable from that for uninfected cells.




FIG. 2. Pattern of protein synthesis in uninfected and infected *gro*⁺ and *gro*₁₀₉ cells. C-2128 (*gro*⁺) and C-2118 (*gro*₁₀₉) were UV-irradiated, infected, and labeled with [³⁵S]methionine as described in *Materials and Methods*. Infection was with P2 *vir*₃ and P2 *vir*₃ *ogr*₅, as indicated. Identification of P2 proteins is described by Lengyel *et al.* (26, 29) and Lengyel and Calendar (30). Proteins H, P, F₁, N, N*, O, and B are P2 late proteins; B is an early protein.

Table 3. Detection of P2 mRNA

Bacteria	Phage	mRNA (% input hybridized)*		
		Early	Late	
		5 min	20 min	45 min
<i>gro</i> ⁺	—	0.018	0.003	—
<i>gro</i> ⁺	P2	0.46	1.5	—
<i>gro</i> ⁺	P2 <i>ogr</i> ₅	0.38	0.53	—
<i>gro</i> ₁₀₉	—	0.002	0.003	0.003
<i>gro</i> ₁₀₉	P2	0.43	0.039	0.20
<i>gro</i> ₁₀₉	P2 <i>ogr</i> ₅	0.21	1.0	3.6

Cultures were pulse-labeled for 3 min at the indicated times after dilution into warm medium, as described in *Materials and Methods*. Values are the average of two or three determinations. Counts retained on blank filters averaged 80 cpm (range: 30–150 cpm) and were subtracted from values obtained on DNA-loaded filters. Both P2 phage strains carried the *vir*₃ marker.

* Input: 1.5 to 2.2 × 10⁶ cpm, early; 3 to 8 × 10⁵ cpm, late.

Synthesis of early P2 mRNA

No detectable late P2 mRNA is made early after infection (5). Hence, presence of early P2 mRNA may be assayed directly by hybridization to P2 DNA. Table 3 shows the results of hybridization experiments in which *gro*⁺ and *gro*₁₀₉ cells were infected with P2⁺ and then labeled with [³H]uridine, followed by extraction of RNA and hybridization to DNA from the appropriate phage. At 5 min after infection with P2 *vir*₃, approximately equal amounts of early P2 mRNA are present in both *gro*⁺ and *gro*₁₀₉ hosts. Thus, *gro*₁₀₉ does not appear to affect early P2 transcription.

Synthesis of late P2 mRNA

The amount of late P2 mRNA made in P2-infected *E. coli gro*₁₀₉ was measured by hybridization to phage Hy5, which carries only late P2 genes and is not homologous to P2 in the early region (19) (Table 3). Very little late P2 mRNA was detected in P2 *ogr*⁺-infected *gro*₁₀₉ cells at 20 min, about 2% of that found in P2 *ogr*⁺-infected *gro*⁺ cells. At 45 min, which is after the normal lysis time, somewhat more late P2 mRNA was detected in P2 *ogr*⁺-infected *gro*₁₀₉ cells. Late P2 mRNA is synthesized at normal levels in P2 *ogr*₅-infected *E. coli gro*₁₀₉ or *gro*⁺ cells. Thus, the *gro*₁₀₉ mutation greatly reduces late P2 transcription.

Dominance of P2 *ogr* mutants

To determine whether the *ogr* mutation affects a site or a phage gene product, complementation tests were performed. The results of one such test, shown in Table 4, demonstrate that P2 *tsD*₄ *ogr*₅ can complement P2 *ogr*⁺ in *E. coli gro*₁₀₉ at 42° to produce a burst of both parental phage types. The P2 *ogr* mutant thus allows expression of the late gene D on the P2 *ogr*⁺ genome. We conclude that the *ogr* mutation is *trans*-dominant to the *ogr*⁺ allele and that P2 *ogr* mutants supply a gene product which allows phage development in *gro*₁₀₉ cells.

Mapping of a P2 *ogr* mutation

The phage crosses listed in Table 5 place the *ogr* gene on the left arm of the P2 genome between the right-most tail gene D and the phage attachment site. Crosses 1 and 2 place the *ogr* gene to the left of the attachment site, as Lindahl (31) has shown that for markers which span the P2 attachment

Table 4. Complementation between P2 *ogr* and P2 *ogr*⁺ in *gro*₁₀₉ cells

Host strain and relevant genotype	Infecting phage	Phage burst
C-2111	P2 <i>vir</i> ₃	0.04
<i>gro</i> ₁₀₉	P2 <i>vir</i> ₃ <i>tsD</i> ₄ <i>ogr</i> ₅	0.01
	P2 <i>vir</i> ₃ <i>ogr</i> ₅	173
	P2 <i>vir</i> ₃	54 { 16 P2 <i>vir</i> ₃ 38 P2 <i>vir</i> ₃ <i>tsD</i> ₄ <i>ogr</i> ₅
	P2 <i>vir</i> ₃ <i>tsD</i> ₄ <i>ogr</i> ₅	
	mixed	

Complementation tests were performed at 42° as described by Lindahl (21).


region (*att*), recombination is largely *int* promoted (approximately 100-fold greater than non-*int* promoted recombination). Cross 3 indicates that *ogr*₅ is located closer to gene D than to gene E. Crosses 4 and 5 place *ogr* between gene D and the phage attachment site.

DISCUSSION

We have shown that an *E. coli* mutation, called *gro*₁₀₉, blocks the multiplication of bacteriophage P2 and prevents

Table 5. Phage crosses

Phage cross	Parental types	Selection	Frequency of unselected marker
1	<i>tsD ogr</i> + + + <i>tsB</i>	<i>ts</i> ⁺	224/250 = <i>ogr</i> ⁺
2	+ <i>ogr</i> <i>amB</i> <i>amD</i> + +	<i>am</i> ⁺	3/99 = <i>ogr</i> ⁺
3	+ <i>tsD ogr</i> <i>amE</i> + +	<i>am</i> ⁺ <i>ts</i> ⁺	63/75 = <i>ogr</i> ⁺
4	+ <i>tsD ogr</i> <i>amU</i> + +	<i>ts</i> ⁺ <i>ogr</i>	73/97 = <i>amU</i>
5	+ <i>tsD ogr</i> <i>amT</i> + +	<i>ts</i> ⁺ <i>ogr</i>	69/100 = <i>amT</i>



The parental phage strains are described in detail in *Materials and Methods*. The gene order deduced is inserted into a comprehensive genetic map, derived from Lindahl (23) and Sunshine *et al.* (10). Arrows indicate direction of transcription. Phage were treated with UV to 50% survival before crossing.

the transcription of late genes. Mutants of P2 that overcome the *gro*₁₀₉ block have been isolated and are called P2 *ogr*. The *trans*-dominance of P2 *ogr* in mixed infection with P2 *ogr*⁺ indicates that P2 *ogr* codes for a diffusible gene product.

The *gro*₁₀₉ mutation is recessive to the wild-type allele, and is tightly linked to a cluster of ribosomal protein genes near the *str* locus. We suspect that *gro*₁₀₉ may be a ribosome-associated protein. This view is strengthened by the finding of Jaskunas and Nomura that a *gro*⁺ gene lies within the cluster of ribosomal protein genes from the *str-spc* region of *E. coli* K-12 that are carried by λ *spc1* and λ *spc2* (ref. 32; personal communication).

Replication of P2 *ogr*⁺ DNA, which requires the P2 early gene products A and B (4, 22), proceeds normally in *gro*₁₀₉ cells. P2 late proteins are not made, however, and the production of P2 late mRNA is greatly reduced. The production of early mRNA and early protein B appears unaffected.

The expression of P2 late genes may thus involve an interaction between a phage gene product (*ogr*⁺) and a component of the translation apparatus (*gro*⁺). Such an interaction could occur in one of several ways. For example, transcription of late P2 genes may require a host protein factor which is also needed for translation. This would be analogous to the situation found in the production of Q β phage RNA (33, 34). Alternatively, P2 late gene transcription may be greatly influenced by the translational process itself. Stent (35, 36) has suggested that ribosome binding to nascent mRNA could enhance the rate of transcription. Since P2 late mRNA but not early mRNA synthesis is affected by *gro*₁₀₉, a third alternative could be that the P2 *ogr*⁺ product somehow modifies the *E. coli gro*₁₀₉⁺ product, allowing transcription of P2 late genes. The *gro*₁₀₉ and *ogr* gene products must be purified before we can distinguish between the above possibilities.

It is clear that the P2 *ogr* gene is essential for phage production in *E. coli gro*₁₀₉. Although conditional lethal mutants of P2 *ogr*⁺ have not yet been isolated, we suspect that *ogr*⁺ is an essential gene in *E. coli gro*⁺, by analogy with the related phage 186. The essential gene of phage 186, defined by *am*₁₇, maps at a location corresponding to *ogr* and is needed for cell lysis and phage particle formation (S. Hocking and J. B. Egan, personal communication).

The unusual location of *ogr* on the P2 genetic map raises the question of how its expression might be controlled. Sunshine (unpublished results) has shown that *ogr* is not under direct immunity control nor under split operon control as is the *int* gene (37). The *cis*-acting product of P2 gene A is needed for *ogr* gene expression (Sunshine, unpublished results). In this respect, the *ogr* gene is similar to the 18 P2 late genes, and unlike the early gene B (23, 37). It seems unlikely that *ogr* is part of the FETUD transcription unit, since the *ogr* product is needed for expression of those genes.

We are indebted to Drs. E. W. Six and R. Calendar for advice and encouragement. M.S. is grateful to Drs. M. Lieb and I. Gordon for the hospitality of their facilities where part of this work was performed. Spectinomycin sulfate was the generous gift of The Upjohn

Co., Kalamazoo, Mich. This work was supported by U.S. Public Health Service Grants AI-04043, AI-05367, and AI-08722 from the National Institute of Allergy and Infectious Diseases, by Training Grants GM-01389 from the National Institute of General Medical Sciences and NIH-USPHS 52-2107-6457, and by Grant BMS-74-19607 from the National Science Foundation.

1. Calendar, R., Lindqvist, B., Sironi, G. & Clark, A. J. (1970) *Virology* **40**, 72-83.
2. Bertani, G. (1951) *J. Bacteriol.* **62**, 293-300.
3. Woods, W. H. & Egan, J. B. (1972) *J. Bacteriol.* **111**, 303-307.
4. Lindqvist, B. H. (1971) *Mol. Gen. Genet.* **110**, 178-196.
5. Geisselsoder, J., Mandel, M., Calendar, R. & Chatteraj, D. K. (1973) *J. Mol. Biol.* **77**, 405-415.
6. Bertani, G. & Weigle, J. J. (1953) *J. Bacteriol.* **65**, 113-121.
7. Sasaki, I. & Bertani, G. (1965) *J. Gen. Microbiol.* **40**, 365-376.
8. Bertani, G. & Six, E. (1958) *Virology* **6**, 357-381.
9. Wiman, M., Bertani, G., Kelly, B. & Sasaki, I. (1970) *Mol. Gen. Genet.* **107**, 1-31.
10. Sunshine, M. G., Thorn, M., Gibbs, W., Calendar, R. & Kelly, B. (1971) *Virology* **46**, 691-702.
11. Lindqvist, B. H. & Sinsheimer, R. L. (1967) *J. Mol. Biol.* **28**, 87-94.
12. Low, B. (1968) *Proc. Nat. Acad. Sci. USA* **60**, 160-167.
13. Dürwald, H. & Hoffman-Berling, H. (1968) *J. Mol. Biol.* **34**, 331-346.
14. Taylor, A. L. & Trotter, C. D. (1972) *Bacteriol. Rev.* **36**, 504-524.
15. Denhardt, D. T., Dressler, D. H. & Hathaway, A. (1967) *Proc. Nat. Acad. Sci. USA* **57**, 813-820.
16. Bertani, G., Choe, B. K. & Lindahl, G. (1969) *J. Gen. Virol.* **5**, 97-104.
17. Bertani, L. E. (1957) *Virology* **4**, 53-71.
18. Baldwin, R. L., Barrand, P., Fritsch, A., Goldthwait, D. A. & Jacob, F. (1966) *J. Mol. Biol.* **17**, 343-357.
19. Younghusband, H. B., Egan, J. B. & Inman, R. B. (1975) *Mol. Gen. Genet.*, in press.
20. Six, E. (1961) *Virology* **14**, 220-233.
21. Lindahl, G. (1969) *Virology* **39**, 839-860.
22. Lindahl, G. (1970) *Virology* **42**, 522-533.
23. Lindahl, G. (1971) *Virology* **46**, 620-633.
24. Sunshine, M. G. & Kelly, B. L. (1967) *Virology* **32**, 644-653.
25. Lindqvist, B. & Six, E. W. (1971) *Virology* **43**, 1-7.
26. Lengyel, J. A., Goldstein, R. N., Marsh, M., Sunshine, M. G. & Calendar, R. (1973) *Virology* **53**, 1-23.
27. Thomas, C. A. & Abelson, J. (1966) in *Procedures in Nucleic Acid Research*, eds. Cartoni, G. L. & Davies, D. R. (Harper and Row, New York), pp. 553-561.
28. Nomura, M. & Engbaek, F. (1972) *Proc. Nat. Acad. Sci. USA* **69**, 1526-1530.
29. Lengyel, J. A., Goldstein, R. N., Marsh, M. & Calendar, R. (1974) *Virology* **62**, 161-174.
30. Lengyel, J. A. & Calendar, R. (1974) *Virology* **57**, 305-313.
31. Lindahl, G. (1969) *Virology* **39**, 861-866.
32. Jaskunas, S. R., Lindahl, L. & Nomura, M. (1975) *Proc. Nat. Acad. Sci. USA* **72**, 6-10.
33. Wahba, A. J., Miller, M. J., Niveleau, A., Landers, T. A., Carmichael, G. G., Weber, J., Hawley, D. A. & Slobin, L. I. (1974) *J. Biol. Chem.* **249**, 3314-3316.
34. Blumenthal, T., Landers, T. A. & Weber, K. (1972) *Proc. Nat. Acad. Sci. USA* **69**, 1313-1317.
35. Stent, G. S. (1964) *Science* **144**, 816-820.
36. Stent, G. S. (1966) *Proc. R. Soc. London Ser. B* **164**, 181-197.
37. Bertani, L. E. (1970) *Proc. Nat. Acad. Sci. USA* **65**, 331-336.